recombinant CD40-ligand

Phase 2Biologic

recombinant CD40-ligand is one of 74 biologic programs targeting Advanced or Metastatic Solid Tumors. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced or Metastatic Solid TumorsActive, not recruiting

PembrolizumabCompleted

Advanced or Metastatic Solid TumorsPhase 1

Active, not recruiting

PembrolizumabPhase 2

Completed

Competition

Competitive Landscape

80 competitors in Advanced or Metastatic Solid Tumors

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 2

20 2

Opdivo

Bristol-Myers Squibb

Phase 2

4 3

Gemzar

Johnson & Johnson

Phase 2

4 4

Taxol

Teva

Phase 2

4 5

Eloxatin

Teva

Phase 2

2 6

Avastin

Roche

Phase 2

1 7

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 2

7 8

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 2

1 9

Platinum

Bristol-Myers Squibb

Phase 2

1 10

Mfolfox6

Roche

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Pembrolizumab

NCT02717156

Clinical

Trials by Indication[1]

Prostate Cancer2 trials

sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Unknown status·NNorthwestern University·Phase 2·NCT04033432·14 enrolled

sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney Cancer

Terminated·UUniversity of Southern California·Phase 1·NCT02767921·2 enrolled

Pembrolizumab2 trials

Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475

Completed·UUniversity of Southern California·Phase 2·NCT03049618·42 enrolled

Multicohort Phase II Trial of sEphB4-HSA+Pembrolizumab in Solid Tumors

Active, not recruiting·UUniversity of Southern California·Phase 2·NCT02717156·103 enrolled

Melanoma2 trials

Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma

Terminated·UUniversity of Southern California·Phase 2·NCT00006113·25 enrolled

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

Completed·UUniversity Hospital Erlangen·Phase 1/2·NCT00053391·62 enrolled

Metastatic Melanoma1 trial

Biological Therapy in Treating Patients With Metastatic Melanoma or Metastatic Kidney Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00020540

Advanced or Metastatic Solid Tumors1 trial

Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors

Active, not recruiting·UUniversity of Southern California·Phase 1·NCT02495896·61 enrolled

5 more indications

Chronic Myelomonocytic Leukemia1 trial

Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent

Terminated·UUniversity of Southern California·Phase 2·NCT03146871·7 enrolled

Acute Leukemia1 trial

EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia

Terminated·UUniversity of Southern California·Phase 1·NCT03519984·3 enrolled

Bladder Cancer1 trial

sEphB4-HSA in Treating Participants With BCG-Unresponsive or Refractory Bladder Cancer

Withdrawn·UUniversity of Southern California·Phase 1·NCT03552796

Kaposi Sarcoma1 trial

sEphB4-HSA in Treating Patients With Kaposi Sarcoma

Completed·AAIDS Malignancy Consortium·Phase 2·NCT02799485·23 enrolled

Solid Tumors1 trial

Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors

Terminated·UUniversity of Southern California·Phase 1·NCT01642342·102 enrolled

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for recombinant CD40-ligand. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — recombinant CD40-ligand compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for recombinant CD40-ligand. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Southern California company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: UUniversity of Southern California

recombinant CD40-ligand

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Prostate Cancer2 trials

Pembrolizumab2 trials

Melanoma2 trials

Metastatic Melanoma1 trial

Advanced or Metastatic Solid Tumors1 trial

Chronic Myelomonocytic Leukemia1 trial

Acute Leukemia1 trial

Bladder Cancer1 trial

Kaposi Sarcoma1 trial

Solid Tumors1 trial

References

Drug Info

Quick Facts

Related News